Latest News

Entrada Therapeutics to Present at Cowen and Company 40th Annual Healthcare Conference

February 25, 2020

BOSTON, Mass. – February 25, 2020 – Entrada Therapeutics, Inc., a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases through the development of intracellular biologics, today announced that Dipal Doshi, President and Chief Executive Officer, will present at the Cowen and Company 40th Annual Healthcare Conference in Boston on Monday, March 2, 2020 at 9:30 a.m. Eastern Standard Time.

About Entrada Therapeutics 

Entrada Therapeutics’ mission is to treat devastating diseases by developing intracellular biologics. Using its proprietary EEV technology, Entrada is creating a diverse pipeline of enzyme, oligonucleotide, protein and peptide programs to efficiently engage intracellular disease targets across multiple therapeutic areas. The Company’s novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the field of intracellular biologics. Entrada, a privately-held company, raised $59 million in a Series A financing in December 2018. The financing was co-led by 5AM Ventures and MPM Capital, along with Roche Venture Fund, MRL Ventures Fund and Agent Capital. For more information, please visit


Investor Contact:

Courtney Dugan

W2O Group

Company Contact: 

Cecilia Sun

Entrada Therapeutics, Inc.


Our technology is based on the ground-breaking research by our scientific founders
Learn More